myLaminin Perspectives

The new ICH E6(R3) guidelines are transforming clinical research worldwide, requiring Quality-by-Design, risk-based oversight, and validated digital systems. Discover how myLaminin's co-designed Clinical Trial Operations (CTOps) and CTMS platform helps research teams, principal investigators, administrators, and compliance professionals streamline operations, strengthen data integrity, improve audit readiness, and meet evolving global regulatory requirements with confidence.

Learn how ICH E6 (R3) is reshaping clinical trials through risk-based quality management, decentralized research oversight, data integrity, and continuous inspection readiness across global clinical research operations.

ICH E6 (R3) is reshaping clinical trial compliance across Canada, the U.S., EU, UK, and Australia. The updated Good Clinical Practice (GCP) guideline emphasizes Quality by Design, proactive risk management, audit trail traceability, sponsor oversight, informed consent, data integrity, and inspection readiness. myLaminin helps research teams and sponsors manage multi-site clinical trials with real-time oversight, CTQ monitoring, compliant eConsent, secure audit trails, and val

Poor clinical trial coordination drives costly delays, data integrity risks, and regulatory exposure across multi-site studies in Canada, the US, and globally. Fragmented systems, inconsistent documentation, and weak communication slow approvals, inflate Phase III costs, and erode patient trust. Integrated CTMS/CR/os platforms like myLaminin unify stakeholders, streamline workflows, strengthen compliance, and enable real-time oversight turning coordination into a competitive